KIT exon 11/17 mutants Inhibitors
1 drugsAbout KIT exon 11/17 mutants
KIT exon 11/17 mutants involve constitutively activated receptor tyrosine kinases that drive uncontrolled cell proliferation. These mutations lead to aberrant KIT signaling, impacting cell growth and survival pathways.
KIT exon 11/17 mutants are a therapeutic target in cancer, though no genetic evidence directly links these mutations to specific diseases. The functional consequence of aberrant KIT activation validates therapeutic intervention.
AYVAKIT (avapritinib) is the only FDA-approved drug targeting KIT exon 11/17 mutants across 6 indications. This small molecule drug was first approved in 2020.
Top KIT exon 11/17 mutants Drugs
BLUEPRINT MEDICINES is the only company with an approved drug targeting KIT exon 11/17 mutants.
The low competitive intensity represents an opportunity for new market entrants.
KIT exon 11/17 mutants Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets KIT exon 11/17 mutants, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
KIT exon 11/17 mutants Clinical Trials 17 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on KIT exon 11/17 mutants. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 4 | 0 | 2 | 100% |
| Phase 2 | 8 | 1 | 0 | 7 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 2 | 1 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
KIT exon 11/17 mutants Drug Approval Timeline (2020 - 2020)
The first and only drug, AYVAKIT, was approved in 2020.
Recent approval suggests a growing interest, but market saturation could occur quickly.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on KIT exon 11/17 mutants. A trial counts if an approved drug acting on KIT exon 11/17 mutants is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.